Interleukins and Human Amnion-Chorion Membranes
Chronic wounds pose a significant global healthcare challenge, often resulting in persistent inflammation and impaired healing. Recent research highlights the critical role of interleukins, particularly IL-1β, in sustaining this inflammatory state, while innovative therapies like dehydrated human amnion/chorion membrane (dHACM) show promise in promoting healing.
This white paper delves into the interplay between these two approaches, exploring how targeting inflammation and enhancing tissue regeneration can transform the management of challenging wounds, such as diabetic foot ulcers and venous leg ulcers. Discover how these advancements revolutionize chronic wound care and improve patient outcomes.
ACA Human Amniotic Chorionic Membrane
Esano ACA is an innovative biological graft that revolutionizes regenerative medicine. This allograft of human amniotic membrane, with its exclusive three-layer structure, offers enhanced therapeutic potential for wound management and tissue repair. Its design not only provides a protective barrier but also facilitates cell migration and adhesion, essential for effective healing. With applications across various medical specialties, Esano ACA stands out as a valuable option for patients with challenging wounds. Here we explore how this product transform wound care clinical practice.